CXL Ophthalmics bags $32m for minimally-invasive treatment for keratoconus
CXL Ophthalmics (CXLO), an American clinical-stage company, has raised $32 million in a Series A funding round for developing a minimally-invasive treatment for keratoconus, a common form of corneal ectasia. The Series A financing round of CXL Ophthalmics was led by AXA IM Alts through its Global Health Private Equity strategy. A syndicate of individual […]